MT Petrucci
YOU?
Author Swipe
View article: Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study Open
Introduction MGRS are new rare clinical entities, whose recognition and optimal management is evolving. Methods To implement real‐life data, we retrospectively analysed a multicentre cohort of 60 patients with renal biopsy‐proven MGRS rece…
View article: P64 A CASE OF COVID-19 PNEUMONIA AFTER CAR T-CELL THERAPY IN A PATIENT AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA
P64 A CASE OF COVID-19 PNEUMONIA AFTER CAR T-CELL THERAPY IN A PATIENT AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA Open
BCMA-targeting chimeric antigen receptor (CAR) T cells proved extremely effective in the treatment of relapsed/refractory (RR) multiple myeloma (MM). Nevertheless, their impact on immune system along with immune impairment induced by previ…
View article: P23: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY.
P23: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY. Open
The overall survival (OS) of multiple myeloma (MM) patients (pts) has improved over the last years due to the introduction of several novel drugs, such as proteosome inhibitors (PI), immunomodulatory drugs (IMiDs) and anti-CD38 monoclonal …
View article: P26: EXTRAMEDULLARY MULTIPLE MYELOMA: A MONOCENTRIC RETROSPECTIVE OBSERVATIONAL STUDY
P26: EXTRAMEDULLARY MULTIPLE MYELOMA: A MONOCENTRIC RETROSPECTIVE OBSERVATIONAL STUDY Open
Extramedullary Multiple Myeloma (EMM) is a distinctive sub-entity of Multiple Myeloma, characterized by clonal plasma-cells proliferation outside the bone marrow; it can be diagnosed either as a tissue growing in contiguity with bone marro…
View article: Coronavirus disease (COVID-19) in patients with multiple myeloma: Reported by the multiple myeloma gimema lazio group
Coronavirus disease (COVID-19) in patients with multiple myeloma: Reported by the multiple myeloma gimema lazio group Open
Infections are the most important cause of mortality in multiple myeloma (MM) patients. In the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) pandemic, known as COVID-19, hematologic malignancies represent an important risk f…
View article: PS1425 RESULTS OF THE DARATUMUMAB MONOTHERAPY EARLY ACCESS TREATMENT PROTOCOL (EAP) IN PATIENTS FROM EUROPE AND RUSSIA WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
PS1425 RESULTS OF THE DARATUMUMAB MONOTHERAPY EARLY ACCESS TREATMENT PROTOCOL (EAP) IN PATIENTS FROM EUROPE AND RUSSIA WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA Open
Background: Daratumumab (DARA) is a human IgGκ monoclonal antibody targeting CD38 that is approved as monotherapy for relapsed or refractory MM (RRMM) and in combination with standard‐of‐care regimens for RRMM and transplant‐ineligible new…
View article: Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point Open
Maintenance therapy has generally been shown to improve outcomes in newly diagnosed multiple myeloma (NDMM).1–8 Increases in progression-free survival (PFS) and overall survival (OS) have been demonstrated in some trials of maintenance the…